No definition available.

Name:	ions_CollaborativeArrangementAndLicensingAgreementAbstract
Namespace Prefix:	ions_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The maximum amount of payments receivable per drug or program for regulatory milestone payments under the collaboration agreement.

+ References

No definition available.

+ Details

Name:	ions_MaximumAmountOfPaymentsReceivablePerDrugOrProgramForRegulatoryMilestones
Namespace Prefix:	ions_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The amount of payments expected to be received under the license agreement.

+ References

No definition available.

+ Details

Name:	ions_PaymentReceivableUnderLicenseAgreement
Namespace Prefix:	ions_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The amount of the payment receivable under the license agreement to be received on the earlier of approval by the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) under the collaboration agreement.

+ References

No definition available.

+ Details

Name:	ions_PaymentReceivableUnderLicenseAgreementToBePaidAfterApproval
Namespace Prefix:	ions_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Period of time before collaboration partner pays royalties on net sales of product after first commercial sale in Brazil, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

No definition available.

+ Details

Name:	ions_PeriodBeforeCollaborationPartnerPaysRoyaltiesOnNetSalesOfProductAfterFirstCommercialSaleInBrazil
Namespace Prefix:	ions_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

The number of separate performance obligations under the collaboration agreement.

+ References

No definition available.

+ Details

Name:	ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations
Namespace Prefix:	ions_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

The minimum amount of revenue recognized in Latin America by the collaboration partner before paying royalties.

+ References

No definition available.

+ Details

Name:	ions_RevenueRecognizedByCollaborationPartnerInLatinAmericaBeforePayingRoyalties
Namespace Prefix:	ions_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Royalty percentage received on the net sales of each drug in Latin America from the collaboration partner under the collaboration agreement.

+ References

No definition available.

+ Details

Name:	ions_RoyaltyPercentageReceivedOnNetSalesOfEachDrugInLatinAmericaFromCollaborationPartner
Namespace Prefix:	ions_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 18
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=109250915&loc=d3e13531-108611

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109250915&loc=d3e13537-108611

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592

+ Details

Name:	us-gaap_ConcentrationRiskPercentage1
Namespace Prefix:	us-gaap_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130532-203044

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045

+ Details

Name:	us-gaap_ContractWithCustomerLiability
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Cash received from licensees for license fees during the current period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585

+ Details

Name:	us-gaap_ProceedsFromLicenseFeesReceived
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueGoodsNetMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=ions_SublicenseRevenueMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ConsolidatedEntitiesAxis=ions_AkceaTherapeuticsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=us-gaap_LicenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaborative Arrangements and Licensing Agreements, PTC Therapeutics (Details) $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended
	Aug. 31, 2018 USD ($) PerformanceObligation	Sep. 30, 2018 USD ($)	Sep. 30, 2017 USD ($)	Sep. 30, 2018 USD ($)	Sep. 30, 2017 USD ($)	Dec. 31, 2017 USD ($)
Collaborative Arrangement and Licensing Agreement [Abstract]
Revenue		$ 145,395	$ 118,314	$ 407,559	$ 346,387
Deferred revenue						$ 233,362
PTC Therapeutics [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Number of separate performance obligations \| PerformanceObligation	2
Revenue		12,000	$ 0	12,000	$ 0
Deferred revenue		$ 0		$ 0		$ 0
PTC Therapeutics [Member] \| Revenue [Member] \| Strategic Partner [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Concentration percentage		8.00%	0.00%	3.00%	0.00%
PTC Therapeutics [Member] \| Sublicense Revenue [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Revenue		$ 7,200
Akcea [Member] \| PTC Therapeutics [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Payment receivable under license agreement		26,000		$ 26,000
Payment received under license agreement		12,000
Payment to be received on earlier of FDA or EMA approval of WAYLIVRA		6,000		6,000
Maximum amount of payments receivable per drug for regulatory milestones		$ 8,000		$ 8,000
Royalty percentage received on net sales of each drug in Latin America from PTC		20.00%
Period before PTC pays royalties on net sales of product after first commercial sale in Brazil				12 months
Minimum revenue recognized in Latin America by PTC before paying royalties		$ 10,000
Akcea [Member] \| PTC Therapeutics [Member] \| License Fees [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Revenue	$ 12,000